Key takeaway
In 9M26, the company recorded revenue growth of 16.5% YoY and a 21.8% YoY increase in Non-IFRS adjusted net profit attributable to shareholders of the parent company. In 3Q26, revenue reached RMB1.788bn, up 24.0% YoY and down 0.9% QoQ, while Non-IFRS adjusted net profit attributable to shareholders of the parent company reached RMB320mn, up 49.6% YoY. In 9M26, the company recorded solid revenue growth in its small-molecule CDMO business, while revenue from emerging businesses grew by more than 50% YoY. New orders signed in 3Q26 increased by approximately 30% YoY, with peptide and oligonucleotide orders growing rapidly. Based on the current backlog awaiting delivery, the company will enter a period of concentrated deliveries in 4Q26. Looking ahead to 2026, the current backlog is sufficient to cover the full-year target. The company maintains its full-year revenue growth guidance of 19%–22%. As orders and deliveries improve, together with higher capacity utilization and operating efficiency, profitability is expected to improve further.
Event
The company released the 9M26 earnings results
In 9M26, the company recorded operating revenue of RMB5.395bn, up 16.5% YoY and 20.0% YoY at constant exchange rates. Net profit attributable to shareholders of the parent company reached RMB852mn, up 6.5% YoY. Adjusted net profit attributable to shareholders of the parent company reached RMB1.074bn, up 21.8% YoY, with an adjusted net margin of 19.9%. Gross margin was 41.9%, up 1.12 pcts YoY at constant exchange rates. New orders signed in 3Q26 increased by approximately 30% YoY. The current backlog is sufficient to cover the full-year target, and the company maintains its guidance for 19%–22% YoY growth in operating revenue in 2026.
Risks:
Subsequent order growth and commercialization business growth may fall short of expectations: The company’s clients are innovative drug companies and multinational pharmaceutical companies, and order growth depends on clients’ innovative project initiation and product R&D progress, which involve uncertainties; Business expansion may fall short of expectations: The company is actively expanding emerging businesses and continuously investing in and building capabilities, and the expansion progress and revenue growth of new businesses involve uncertainties; Risk of loss of core technical personnel: The pharmaceutical outsourcing service industry is a technology-talent-intensive industry, and the company stabilizes its technical team by establishing various talent incentive mechanisms, with no large-scale loss of technical personnel having occurred. If large-scale loss occurs, it will have a negative impact on its normal operations. Capacity expansion and utilizat ion may fall short of expectations: The company’s peptide and biological macromolecules segments are still expanding capacity, and there may be cases where the expansion progress or capacity utilization rate falls short of expectations.



